Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include…
MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market on…
The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setting…
Amyloidosis is caused by the deposition of insoluble amyloid fibrils formed by the accumulation of misfolded proteins into affected organs. Amyloid immunoglobulin light chain (AL), amyloid A (AA…
MARKET OUTLOOK Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as…
MARKET OUTLOOK Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…
Prior to the launch of Hemlibra, the hemophilia market consisted solely of factor-based products. The use of factor concentrate is highly varied; brand-dependent dosing and infusion frequencies,…
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-…
For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved therapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine…
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…